Erlotinib Completed Phase 2 Trials for Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Salivary Gland Cancer / Stage IV Verrucous Carcinoma of the Oral Cavity / Recurrent Verrucous Carcinoma of the Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary / Stage IV Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Salivary Gland Squamous Cell Carcinoma / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01316757Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer